In patients with ischemic stroke, NVAF, and ASCVD, adding an antiplatelet to OAC therapy did not affect net clinical benefit at 2 y.
Where this comes from
- Record sourced from PubMed, PMID 41628452.
- Also identified by DOI 10.7326/ANNALS-25-05308-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
GIM/FP/GP: [Formula: see text] Neurology: [Formula: see text] Hematology: [Formula: see text].
Medical subject headings
- Platelet Aggregation Inhibitors
- Ischemic Stroke
- Anticoagulants
- Stroke